vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
Walker & Dunlop, Inc. is the larger business by last-quarter revenue ($340.0M vs $196.9M, roughly 1.7× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -0.4%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-680.1M). Over the past eight quarters, Walker & Dunlop, Inc.'s revenue compounded faster (22.1% CAGR vs 8.5%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
PCRX vs WD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.9M | $340.0M |
| Net Profit | — | $-13.9M |
| Gross Margin | 79.5% | — |
| Operating Margin | 1.2% | -17.2% |
| Net Margin | — | -12.9% |
| Revenue YoY | 5.1% | -0.4% |
| Net Profit YoY | — | -131.0% |
| EPS (diluted) | $0.05 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.9M | $340.0M | ||
| Q3 25 | $179.5M | $337.7M | ||
| Q2 25 | $181.1M | $319.2M | ||
| Q1 25 | $168.9M | $237.4M | ||
| Q4 24 | $187.3M | $341.5M | ||
| Q3 24 | $168.6M | $292.3M | ||
| Q2 24 | $178.0M | $270.7M | ||
| Q1 24 | $167.1M | $228.1M |
| Q4 25 | — | $-13.9M | ||
| Q3 25 | $5.4M | $33.5M | ||
| Q2 25 | $-4.8M | $34.0M | ||
| Q1 25 | $4.8M | $2.8M | ||
| Q4 24 | — | $44.8M | ||
| Q3 24 | $-143.5M | $28.8M | ||
| Q2 24 | $18.9M | $22.7M | ||
| Q1 24 | $9.0M | $11.9M |
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — | ||
| Q1 24 | 71.6% | — |
| Q4 25 | 1.2% | -17.2% | ||
| Q3 25 | 3.5% | 13.6% | ||
| Q2 25 | 4.7% | 14.5% | ||
| Q1 25 | 1.2% | 2.2% | ||
| Q4 24 | 13.2% | 15.3% | ||
| Q3 24 | -82.8% | 12.8% | ||
| Q2 24 | 15.9% | 10.4% | ||
| Q1 24 | 7.9% | 6.0% |
| Q4 25 | — | -12.9% | ||
| Q3 25 | 3.0% | 9.9% | ||
| Q2 25 | -2.7% | 10.6% | ||
| Q1 25 | 2.8% | 1.2% | ||
| Q4 24 | — | 13.1% | ||
| Q3 24 | -85.1% | 9.9% | ||
| Q2 24 | 10.6% | 8.4% | ||
| Q1 24 | 5.4% | 5.2% |
| Q4 25 | $0.05 | $-0.41 | ||
| Q3 25 | $0.12 | $0.98 | ||
| Q2 25 | $-0.11 | $0.99 | ||
| Q1 25 | $0.10 | $0.08 | ||
| Q4 24 | $0.38 | $1.32 | ||
| Q3 24 | $-3.11 | $0.85 | ||
| Q2 24 | $0.39 | $0.67 | ||
| Q1 24 | $0.19 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.4M | $299.3M |
| Total DebtLower is stronger | $372.2M | — |
| Stockholders' EquityBook value | $693.1M | $1.7B |
| Total Assets | $1.3B | $5.1B |
| Debt / EquityLower = less leverage | 0.54× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $238.4M | $299.3M | ||
| Q3 25 | $246.3M | $274.8M | ||
| Q2 25 | $445.9M | $233.7M | ||
| Q1 25 | $493.6M | $181.0M | ||
| Q4 24 | $484.6M | $279.3M | ||
| Q3 24 | $453.8M | $179.8M | ||
| Q2 24 | $404.2M | $208.1M | ||
| Q1 24 | $325.9M | $216.5M |
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $693.1M | $1.7B | ||
| Q3 25 | $727.2M | $1.8B | ||
| Q2 25 | $757.8M | $1.8B | ||
| Q1 25 | $798.5M | $1.7B | ||
| Q4 24 | $778.3M | $1.7B | ||
| Q3 24 | $749.6M | $1.7B | ||
| Q2 24 | $879.3M | $1.7B | ||
| Q1 24 | $892.2M | $1.7B |
| Q4 25 | $1.3B | $5.1B | ||
| Q3 25 | $1.3B | $5.8B | ||
| Q2 25 | $1.5B | $4.7B | ||
| Q1 25 | $1.6B | $4.5B | ||
| Q4 24 | $1.6B | $4.4B | ||
| Q3 24 | $1.5B | $4.6B | ||
| Q2 24 | $1.6B | $4.2B | ||
| Q1 24 | $1.6B | $3.8B |
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.7M | $-664.3M |
| Free Cash FlowOCF − Capex | $43.5M | $-680.1M |
| FCF MarginFCF / Revenue | 22.1% | -200.0% |
| Capex IntensityCapex / Revenue | 0.1% | 4.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $136.7M | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.7M | $-664.3M | ||
| Q3 25 | $60.8M | $-948.1M | ||
| Q2 25 | $12.0M | $-238.5M | ||
| Q1 25 | $35.5M | $-281.1M | ||
| Q4 24 | $33.1M | $129.4M | ||
| Q3 24 | $53.9M | $-202.0M | ||
| Q2 24 | $53.2M | $-237.8M | ||
| Q1 24 | $49.1M | $38.4M |
| Q4 25 | $43.5M | $-680.1M | ||
| Q3 25 | $57.0M | $-950.4M | ||
| Q2 25 | $9.3M | $-241.0M | ||
| Q1 25 | $26.9M | $-284.7M | ||
| Q4 24 | $31.0M | $116.4M | ||
| Q3 24 | $49.8M | $-204.0M | ||
| Q2 24 | $51.6M | $-241.7M | ||
| Q1 24 | $46.3M | $35.2M |
| Q4 25 | 22.1% | -200.0% | ||
| Q3 25 | 31.7% | -281.5% | ||
| Q2 25 | 5.1% | -75.5% | ||
| Q1 25 | 15.9% | -120.0% | ||
| Q4 24 | 16.6% | 34.1% | ||
| Q3 24 | 29.6% | -69.8% | ||
| Q2 24 | 29.0% | -89.3% | ||
| Q1 24 | 27.7% | 15.4% |
| Q4 25 | 0.1% | 4.6% | ||
| Q3 25 | 2.2% | 0.7% | ||
| Q2 25 | 1.5% | 0.8% | ||
| Q1 25 | 5.1% | 1.5% | ||
| Q4 24 | 1.1% | 3.8% | ||
| Q3 24 | 2.4% | 0.7% | ||
| Q2 24 | 0.9% | 1.4% | ||
| Q1 24 | 1.7% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | -28.34× | ||
| Q2 25 | — | -7.02× | ||
| Q1 25 | 7.37× | -102.07× | ||
| Q4 24 | — | 2.89× | ||
| Q3 24 | — | -7.01× | ||
| Q2 24 | 2.82× | -10.49× | ||
| Q1 24 | 5.47× | 3.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
WD
Segment breakdown not available.
